Drug Trial Radar · NCT04139122
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Apr 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
89
Actual
Start
Oct 5, 2019
Primary completion
Mar 3, 2020
Study completion Mar 3, 2020
Sponsor
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first study in humans to evaluate the effectiveness of SJP-0132 in the treatment of dry eye disease. This study will evaluate the safety, tolerability, efficacy, and pharmacokinetics of single- and multiple-dose regimens of SJP-0132 in subjects with dry eye disease
Conditions
- Dry Eye Disease
- Dry Eye Syndrome
Interventions
SJP-0132Drug
SJP-0132 is administered as an eye drop
PlaceboDrug
Placebo is administered as an eye drop
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events by Severity in Each CohortTime frame: Day 2 for cohort 1-4, Day 29 for cohort 5-6
- Number of Subjects With Abnormal Changes in Laboratory Parameters, Vital Signs, and/or Physical and Ophthalmologic Observations in Each CohortTime frame: Day 2 for cohort 1-4, Day 29 for cohort 5-6
- Maximum Plasma Concentration (Cmax)Time frame: Day 1
- Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration (AUC0-last)Time frame: Day 1
- Accumulation Ratio (Rac) After Multiple DosingTime frame: Day 2, 4, 8
- Change From Baseline in Eye Dryness Symptom (VAS) at 4hour on Day 29Time frame: Day 29
- Change From Baseline in Corneal Fluorescein Staining (CFS) Score at the Central Zone on Day 29Time frame: Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Senju Investigational Site
Cypress, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.